Yes, warfarin (nicoumarin) should be given together with unfractionated heparin in renal vein thrombosis
For renal vein thrombosis, initiate UFH immediately and overlap with warfarin for at least 5 days until the INR reaches 2.0-3.0 for at least 24 consecutive hours before discontinuing heparin. This is the standard approach for treating venous thromboembolism, which includes renal vein thrombosis 1.
Treatment Algorithm
Initial Anticoagulation with UFH
Start UFH using weight-based dosing:
- IV bolus: 80 U/kg
- Continuous infusion: 18 U/kg per hour
- Adjust to maintain aPTT ratio of 1.5-2.5 (corresponding to anti-factor Xa levels of 0.3-0.7 IU/mL) 2
Alternative subcutaneous regimen (if IV access is problematic):
Concurrent Warfarin Initiation
- Start warfarin on day 1 of heparin therapy (do not delay) 1
- Initial dose: typically 5 mg daily (lower doses of 2.5-5 mg for elderly, malnourished, or those with liver disease) 2
- Target INR: 2.0-3.0
Overlap Period
Continue both UFH and warfarin for minimum 5 days AND until INR ≥2.0 for at least 24-48 hours 2, 4, 2, 1. This overlap is critical because:
- Warfarin's anticoagulant effect is delayed (takes 5-7 days to reach full effect)
- Early warfarin paradoxically creates a transient hypercoagulable state by depleting protein C before depleting clotting factors
- Premature heparin discontinuation risks thrombosis extension
Important Monitoring Considerations
During Overlap Therapy
When drawing PT/INR while on both agents, timing matters because heparin can affect the PT/INR 1:
- Draw blood at least 5 hours after last IV heparin bolus
- Or 4 hours after stopping continuous IV infusion
- Or 24 hours after subcutaneous heparin injection
Platelet Monitoring
Monitor platelet count every 2-3 days from day 4 to day 14 of heparin therapy to screen for heparin-induced thrombocytopenia (HIT), which occurs in up to 5% of patients receiving UFH 2. A ≥50% drop in platelets warrants immediate heparin cessation and alternative anticoagulation 5.
Special Considerations for Renal Vein Thrombosis
Renal Function Impact
UFH is the preferred agent in severe renal impairment (CrCl <30 mL/min) because it undergoes hepatic metabolism rather than renal clearance 6, 7, 8, 9. This is particularly relevant since renal vein thrombosis may compromise kidney function.
Low-molecular-weight heparins (LMWH) are contraindicated when CrCl <30 mL/min due to accumulation and increased bleeding risk 2, 10.
Clinical Context
Renal vein thrombosis often occurs in the setting of:
- Nephrotic syndrome (most common in adults)
- Malignancy
- Complicated urinary tract infections 11
- Hypercoagulable states
The presence of these conditions doesn't change the anticoagulation approach but may influence duration of therapy and require investigation for underlying causes.
Common Pitfalls to Avoid
Starting warfarin without heparin: The delayed onset of warfarin's therapeutic effect leaves patients unprotected and at risk for thrombosis extension
Stopping heparin too early: Discontinuing heparin before adequate warfarin effect (INR ≥2.0 for 24-48 hours) creates a dangerous gap in anticoagulation
Using LMWH instead of UFH in renal dysfunction: While LMWH is generally preferred over UFH for VTE 2, UFH is superior when renal function is compromised
Inadequate overlap duration: The minimum 5-day overlap is absolute, regardless of when INR becomes therapeutic 1
Ignoring platelet monitoring: Failure to monitor for HIT can result in catastrophic thrombotic complications 2